COMPARATIVE SAFETY OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS FOR CARDIOVASCULAR AND CANCER OUTCOMES IN RHEUMATOID ARTHRITIS

被引：0
|
作者：
Sendaydiego, X. [1 ]
Gold, L. [2 ]
Lee, J. [3 ]
Goulabchand, R. [4 ]
Hughes, G. [5 ]
Pioro, M. [5 ]
Andrews, J. [5 ]
Makris, U. [6 ]
Suri, P. [7 ]
Jarvik, J. [8 ]
Sparks, J. [9 ]
Singh, S. [10 ]
Singh, N. [5 ]
机构：
[1] Univ Washington, Med, Internal Med Residency, Seattle, WA USA
[2] Univ Washington, Ctr Musculoskeletal Disorders, Clin Learning Evidence & Res CLEAR, Radiol, Seattle, WA USA
[3] Univ Michigan, Med Rheumatol, Ann Arbor, MI USA
[4] CHU Nimes Univ Montpellier, Med, Nimes, France
[5] Univ Washington, Med Rheumatol, Seattle, WA USA
[6] Univ Texas SouthWestern, Med Rheumatol, Dallas, TX USA
[7] Univ Washington, Ctr Musculoskeletal Disorders, Clin Learning Evidence & Res CLEAR, Rehabil Med, Seattle, WA USA
[8] Univ Washington, Radiol, Hlth Serv Res Ctr, Seattle, WA USA
[9] Brigham & Womens Hosp, Med Rheumatol, Boston, MA USA
[10] Univ Calif San Diego, Med Gastroenterol, La Jolla, CA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
基金：
美国国家卫生研究院;
关键词：
Cardiovascular disease; Rheumatoid arthritis; Disease-modifying Drugs (DMARDs);
D O I：
10.1136/annrheumdis-2023-eular.2462
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0398
引用
收藏
页码：1382 / 1383
页数：2
相关论文
共 50 条
  • [1] Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cardiovascular Outcomes in Rheumatoid Arthritis
    Sendaydiego, Xavier
    Gold, Laura
    Wysham, K.
    Liew, Jean
    Dubreuil, Maureen
    Andrews, James
    Reid, Pankti
    Liew, David
    Goulabchand, Radjiv
    Singh, Abha
    Hughes, Grant
    Pioro, Mathilde
    Sparks, Jeffrey
    Jarvik, Jeffrey
    Singh, Siddharth
    Singh, Namrata
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 848 - 850
  • [2] Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis
    Sendaydiego, Xavier
    Gold, Laura S.
    Dubreuil, Maureen
    Andrews, James S.
    Reid, Pankti
    Liew, David F. L.
    Goulabchand, Radjiv
    Hughes, Grant C.
    Sparks, Jeffrey A.
    Jarvik, Jeffrey G.
    Singh, Siddharth
    Liew, Jean W.
    Singh, Namrata
    RHEUMATOLOGY, 2025,
  • [3] Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cancer in Rheumatoid Arthritis
    Sendaydiego, Xavier
    Gold, Laura
    Liew, Jean
    Wysham, K.
    Dubreuil, Maureen
    Andrews, James
    Reid, Pankti
    Liew, David
    Goulabchand, Radjiv
    Singh, Abha
    Hughes, Grant
    Pioro, Mathilde
    Sparks, Jeffrey
    Jarvik, Jeffrey
    Singh, Siddharth
    Singh, Namrata
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3333 - 3336
  • [4] Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence
    Singh, Namrata
    Li, Christopher, I
    CURRENT OPINION IN RHEUMATOLOGY, 2021, 33 (03) : 292 - 299
  • [5] Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs
    Pawar, Ajinkya
    Desai, Rishi J.
    He, Mengdong
    Bessette, Lily
    Kim, Seoyoung C.
    ACR OPEN RHEUMATOLOGY, 2021, 3 (08) : 531 - 539
  • [6] Efficacy and safety of conventional synthetic, biologic, and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-interstitial lung disease: A narrative review
    Conway, Richard
    Corcoran, Luke
    Nikiphorou, Elena
    INDIAN JOURNAL OF RHEUMATOLOGY, 2021, 16 (05) : 92 - 100
  • [7] Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis
    Lee, Bong -Woo
    Lee, Jennifer Jooha
    Kim, Wan-Uk
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2024, 39 (05): : 833 - +
  • [8] Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs
    Baker, Matthew C.
    Liu, Yuhan
    Lu, Rong
    Lin, Janice
    Melehani, Jason
    Robinson, William H.
    JAMA NETWORK OPEN, 2023, 6 (03)
  • [9] Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk
    Sendaydiego, Xavier
    Gold, Laura S.
    Dubreuil, Maureen
    Andrews, James S.
    Reid, Pankti
    Liew, David F. L.
    Goulabchand, Radjiv
    Singh, Abha Goyal
    Hughes, Grant C.
    Pioro, Mathilde
    Sparks, Jeffrey A.
    Jarvik, Jeffrey G.
    Singh, Siddharth
    Liew, Jean W.
    Singh, Namrata
    JAMA NETWORK OPEN, 2024, 7 (11)
  • [10] Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Machado, Marina
    Moura, Cristiano
    Behlouli, Hassan
    Curtis, Jeffrey
    Bernatsky, Sasha
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 937 - 938
12345